Dashboard
Manage Tickers

CRSP CRISPR Therapeutics AG

Nasdaq crisprtx.com


$ 61.76 $ -1.05 (-1.67 %)    

Monday, 03-Nov-2025 19:49:12 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 629.78 $ -3.11 (-0.49 %)
DIA $ 472.70 $ -2.66 (-0.56 %)
SPY $ 681.88 $ -2.29 (-0.33 %)
TLT $ 89.68 $ 0.07 (0.08 %)
GLD $ 366.72 $ 0.05 (0.01 %)
$ 61.97
$ 63.02
$ 61.10 x 2
$ 62.50 x 15
$ 60.53 - $ 64.74
$ 30.04 - $ 78.48
1,922,535
na
5.64B
$ 1.38
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-04-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 02-11-2025 12-31-2024 10-K
4 11-05-2024 09-30-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-21-2024 12-31-2023 10-K
8 11-06-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 02-21-2023 12-31-2022 10-K
12 11-01-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-15-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 07-29-2021 06-30-2021 10-Q
18 04-27-2021 03-31-2021 10-Q
19 02-16-2021 12-31-2020 10-K
20 10-28-2020 09-30-2020 10-Q
21 07-27-2020 06-30-2020 10-Q
22 04-28-2020 03-31-2020 10-Q
23 02-12-2020 12-31-2019 10-K
24 10-28-2019 09-30-2019 10-Q
25 07-29-2019 06-30-2019 10-Q
26 04-29-2019 03-31-2019 10-Q
27 02-25-2019 12-31-2018 10-K
28 11-07-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 03-08-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-10-2017 06-30-2017 10-Q
34 05-11-2017 03-31-2017 10-Q
35 03-10-2017 12-31-2016 10-K
36 11-22-2016 09-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

intellia-freezes-key-trial-after-serious-liver-event-stock-tumbles
Intellia Freezes Key Trial After Serious L...
10/27/2025 14:38:29

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related advers...

b-of-a-securities-maintains-buy-on-crispr-therapeutics-raises-price-target-to-93
B of A Securities Maintains Buy on CRISPR ...
10/17/2025 11:16:40

B of A Securities analyst Geoff Meacham maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target f...

needham-reiterates-buy-on-crispr-therapeutics-maintains-81-price-target
Needham Reiterates Buy on CRISPR Therapeut...
10/10/2025 15:04:22

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $81 price target.

crispr-therapeutics-reports-new-preclinical-data-from-syntase-gene-editing-platform-for-treatment-of-alpha-1-antitrypsin-deficiency
CRISPR Therapeutics Reports New Preclinica...
10/10/2025 12:13:27

-Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profil...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/08/2025 17:35:32

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/03/2025 17:35:44

crispr-therapeutics-to-present-preclinical-data-on-alpha-1-antitrypsin-deficiency-utilizing-novel-syntase-gene-editing-technology
CRISPR Therapeutics To Present Preclinical...
10/01/2025 12:04:16

hc-wainwright--co-reiterates-buy-on-crispr-therapeutics-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on CRIS...
09/23/2025 10:59:59

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $80...

crispr-therapeutics-and-sirius-therapeutics-announce-first-patient-dosed-in-phase-2-clinical-trial-of-srsd107-factor-xi-sirna-for-prevention-of-vte-in-patients-undergoing-tka
CRISPR Therapeutics And Sirius Therapeutic...
09/22/2025 12:34:00

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...

my-top-biotech-stock-picks-and-portfolio-strategy-for-the-next-3-10-years
My Top Biotech Stock Picks And Portfolio S...
09/18/2025 17:10:48

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...

jp-morgan-initiates-coverage-on-crispr-therapeutics-with-overweight-rating-announces-price-target-of-70
JP Morgan Initiates Coverage On CRISPR The...
09/18/2025 10:55:54

JP Morgan analyst Brian Cheng initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Overweight rating and announces...

how-is-the-market-feeling-about-crispr-therapeutics
How Is The Market Feeling About CRISPR The...
09/12/2025 18:00:46

Core News & Articles
10 Health Care Stocks Whale Activity In To...
09/02/2025 17:35:29

peering-into-crispr-therapeuticss-recent-short-interest
Peering Into CRISPR Therapeutics's Recent ...
08/22/2025 13:00:48

cathie-woods-arkk-is-beating-big-tech-like-its-2020-again--but-with-a-twist
Cathie Wood's ARKK Is Beating Big Tech Lik...
08/19/2025 15:40:03

Cathie Wood's ARK Innovation ETF is outperforming tech market again in 2025, driven by AI breakthroughs and the return of i...

cathie-woods-top-10-stock-picks-unpacking-ark-funds-innovation-picks-for-the-next-decade
Cathie Wood's Top 10 Stock Picks: Unpackin...
08/14/2025 17:02:25

Ark Invest has six main ETFs with several around for more than 10 years. A look at the top 10 holdings across the six funds and...

hc-wainwright--co-maintains-buy-on-crispr-therapeutics-raises-price-target-to-80
HC Wainwright & Co. Maintains Buy on CRISP...
08/07/2025 11:54:08

HC Wainwright & Co. analyst Mitchell Kapoor maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price ...

barclays-maintains-equal-weight-on-crispr-therapeutics-raises-price-target-to-56
Barclays Maintains Equal-Weight on CRISPR ...
08/06/2025 14:11:44

Barclays analyst Gena Wang maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and raises the price target from ...

cathie-woods-ark-dumps-block-stock-worth-48-million-as-bitcoin-heavy-company-preps-q2-results
Cathie Wood's Ark Dumps Block Stock Worth ...
08/06/2025 01:48:06

Cathie Wood-led Ark Invest executed a significant trade in Block Inc. (NYSE:XYZ) on Tuesday.

chardan-capital-maintains-buy-on-crispr-therapeutics-maintains-82-price-target
Chardan Capital Maintains Buy on CRISPR Th...
08/05/2025 22:19:41

Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $82 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION